PBAC's latest decision on Macrogol 3350: Recommended with restriction (2007). Considered for chronic constipation or faecal impaction not adequately controlled with first line interventions such as bulk-forming agents; patients with malignant neoplasia, paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
3
first 2005
Submissions
3
2005 → 2007
Eligible population
patients with chronic constipation or faecal impaction not adequately controlled with first line interventions such as bulk-forming agents; patients with malignant neoplasia, paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function
Therapy area
Gastroenterology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
QoL
Key trials
Attar (1999), MOV-PARK (2001), Lenmann (1994), Wang (2004), Thomson (2004)
Economic model
Not modelled
ICER note
No economic evaluation generated by the sponsor was presented. Five published pharmacoeconomic studies were cited but no ICER values are stated in the document.
Submission history
Nov 2005: Not recommended
Mar 2007: Recommended with restriction · Restricted benefit
Nov 2007: Recommended with restriction · Restricted